eligibility_summary
Eligible: adults (≥18) with newly diagnosed B‑precursor Ph+ ALL, ECOG 0–1, consented, ineligible for allo‑HSCT, adequate renal/hepatic (AST/ALT/AP <2×ULN, CrCl ≥50), pancreatic (amylase/lipase ≤1.5×ULN), normal cardiac, negative HIV/HBV DNA/HCV RNA, negative pregnancy test if WOCBP. Exclude: prior systemic chemo/CAR‑T, significant cardiac disease/QTc>450/recent MI, GI malabsorption, autoimmune/CNS disease or CNS leukemia, other cancers, active infection, pregnancy/lactation/no contraception, PI decision.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase 2, single-arm “ABC” regimen for newly diagnosed Ph+ ALL. Interventions/mechanisms: • Olverembatinib (oral third‑generation BCR::ABL1 tyrosine kinase inhibitor/TKI, active vs T315I, suppresses BCR‑ABL signaling pathways incl. RAS/MAPK, PI3K/AKT, STAT5). • Blinatumomab (CD3/CD19 bispecific T‑cell engager/BiTE, redirects CD3+ T cells to kill CD19+ B‑precursor blasts). • Chidamide/tucidinostat (selective histone deacetylase inhibitor, HDAC1/2/3/10, epigenetic modulation that may restore IKZF1 function, increase CD19 expression, and sensitize leukemia to T‑cell therapy). • Prednisone prephase (glucocorticoid, lympholytic). Target cells/pathways: CD19+ Ph+ B‑precursor ALL blasts, BCR::ABL1 oncogenic kinase signaling, CD3+ T‑cell activation/synapse formation, epigenetic/IKZF1 (Ikaros) axis, including high‑risk IKZF1del subgroup.